Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis

Background. Immune checkpoint inhibitors (ICIs) have been evaluated as neoadjuvant treatment in urothelial carcinoma (UC) patients, with these agents reporting encouraging pathologic complete response (pCR) rates. Herein, we performed a systematic review and meta-analysis aimed at evaluating the inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Rizzo, Alessandro, Mollica, Veronica, Santoni, Matteo, Palmiotti, Gennaro, Massari, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880201/
https://www.ncbi.nlm.nih.gov/pubmed/35207311
http://dx.doi.org/10.3390/jcm11041038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880201/
https://www.ncbi.nlm.nih.gov/pubmed/35207311
http://dx.doi.org/10.3390/jcm11041038

Ejemplares similares